BioCanRx has partnered with the Ontario Institute for Cancer Research (OICR) and several other groups to provide funding and support for two new Clinical, Social, and Economic Impact (CSEI) projects led by Drs. Kelvin Chan and Kednapa Thavorn.
The objective of the CSEI Program is to develop potential solutions to social, legal, ethical, economic or health-systems barriers facing BioCanRx biotherapeutic products and platforms as they progress through the translational pipeline from preclinical research to clinical trials.
Dr. Kelvin Chan, of Sunnybrook Research Institute, is the lead investigator for the project titled:
Assessing the Real-World Clinical and Economic Outcomes of Emerging Innovative Technologies in Oncology: The Cases of Biosimilars and CAR T-cells
Dr. Kednapa Thavorn, of the Ottawa Hospital Research Institute, is the lead investigator for the project titled:
Using real-world data and iterative economic evaluation to prioritize resource allocation for care and research in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia